IceCure Medical Ltd. Files 6-K Report
Ticker: ICCM · Form: 6-K · Filed: Aug 13, 2025 · CIK: 1584371
Sentiment: neutral
Topics: financial-report, 6-K, foreign-private-issuer
Related Tickers: ICUR
TL;DR
ICUR filed a 6-K for Q2 2025 results, check for details.
AI Summary
IceCure Medical Ltd. filed a Form 6-K on August 13, 2025, reporting its unaudited interim financial results for the period ending June 30, 2025. The filing is a routine report for foreign private issuers and does not contain specific financial figures in the provided text.
Why It Matters
This filing provides an update on the company's financial performance and operational status for investors and regulatory bodies.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material information or significant events.
Key Players & Entities
- IceCure Medical Ltd. (company) — Registrant
- 0001213900-25-075311 (filing_id) — Accession Number
- 20250813 (date) — Filing Date
- 20250630 (date) — Reporting Period End Date
FAQ
What type of financial information is being reported in this 6-K?
This 6-K reports the Company's unaudited interim financial results.
What is the reporting period for the financial information in this filing?
The conformed period of report is June 30, 2025.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on August 13, 2025.
Is IceCure Medical Ltd. required to file annual reports on Form 20-F or 40-F?
Yes, IceCure Medical Ltd. files annual reports under cover of Form 20-F.
What is the principal executive office address for IceCure Medical Ltd.?
The principal executive office is located at 7 Ha'Eshel St., PO Box 3163, Caesarea, 3079504, Israel.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-08-13 08:35:37
Filing Documents
- ea0252582-6k_icecure.htm (6-K) — 18KB
- ea025258201ex99-1_icecure.htm (EX-99.1) — 244KB
- ea025258201ex99-2_icecure.htm (EX-99.2) — 104KB
- ea025258201ex99-3_icecure.htm (EX-99.3) — 87KB
- 0001213900-25-075311.txt ( ) — 2505KB
- icm-20250630.xsd (EX-101.SCH) — 31KB
- icm-20250630_cal.xml (EX-101.CAL) — 33KB
- icm-20250630_def.xml (EX-101.DEF) — 121KB
- icm-20250630_lab.xml (EX-101.LAB) — 231KB
- icm-20250630_pre.xml (EX-101.PRE) — 134KB
- ea0252582-6k_icecure_htm.xml (XML) — 197KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IceCure Medical Ltd. Date: August 13, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2